Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity
Nexalin Technology Awarded Key Patent Related To Gen-3 HALO Clarity
Mark White, CEO of Nexalin Technology, stated, "This method of use patent award marks a major achievement for the Company and follows another recent patent covering our core technology. These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety. A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin's Virtual Clinic."
Nexalin Technology首席執行官馬克·懷特表示：“這項使用方法專利獎標誌着公司的一項重大成就，也是繼最近又一項涵蓋我們核心技術的專利之後。這些專利有效期至2040年，是我們總體戰略的關鍵要素，因爲越來越多的臨床數據支持我們的無創深頻腦刺激技術在失眠、抑鬱和焦慮領域的益處。我們的新Gen-3 HALO Clarity的一個關鍵差異化因素是，它首次使患者能夠在自己的家中私密地接受這種治療，並由Nexalin虛擬診所的醫生進行遠程監控。”
譯文內容由第三人軟體翻譯。